Cannabis Nanoplatform Treats Menopause Symptoms, Published 23rd Apr
Summary
USPTO published patent application US20260108538A1 (filed October 21, 2024) for a cannabinoid-based nanoplatform composition targeting menopause symptoms. The composition combines phytocannabinoids (CBD, CBG, CBN) with isoflavones and polyphenols in a nanoplatform designed for enhanced bioavailability and controlled release. The disclosed kit includes oral capsules and intravaginal ovules formulated to address vasomotor symptoms, genitourinary syndrome of menopause, bone loss, mood disturbances, sleep disorders, and cardiovascular disease risks.
“The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published application US20260108538A1 discloses a cannabinoid-based nanoplatform composition incorporating CBD, CBG, CBN, isoflavones, and polyphenols for treating menopause symptoms including vasomotor symptoms, genitourinary syndrome, bone loss, mood disturbances, sleep disorders, and cardiovascular risks. The formulation uses nanoplatform technology for enhanced bioavailability and controlled release, delivered via oral capsules and intravaginal ovules.
Pharmaceutical companies developing cannabinoid-based therapeutics should monitor this application for potential freedom-to-operate implications. The combination of specific phytocannabinoids with isoflavones and polyphenols in nanoplatform form represents a disclosed approach to menopause symptom management that may affect competitive positioning in the women's health and cannabinoid therapeutics space.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CANNABINOID BASED NANOPLATFORM COMPOSITION AND METHODS FOR TREATING MENOPAUSE SYMPTOMS
Application US20260108538A1 Kind: A1 Apr 23, 2026
Assignee
Cannabis Bioscience International Holdings Inc
Inventors
Rosangel del Valle Andrades Fuentes, Nancy Paola Duarte Delgado, Nancy Rodrigues Das Fontes, Stephanie Dona Hartmann, Ana Maria Maldonado Vacca, Maria Angelica Clavijo Romero
Abstract
Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.
CPC Classifications
A61K 31/658 A61K 9/02 A61K 9/4825 A61K 9/4858 A61K 31/05 A61K 31/352 A61K 36/48 A61K 47/14 A61K 47/22 A61K 47/44
Filing Date
2024-10-21
Application No.
18921140
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.